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The chemical space taken by pro-
teoforms is immense. Somewhat
overlooked in recent literature are
proteoforms that differ at their amino-
termini, N-terminal proteoforms.
Diverse molecular mechanisms create
N-terminal proteoforms.
Mainly atomistic studies have revealed
different functions of N-terminal pro-The collection of chemically different protein variants, or proteoforms, by far ex-
ceeds the number of protein-coding genes in the human genome. Major contribu-
tors are alternative splicing and protein modifications. In this review, we focus on
those proteoforms that differ at their N termini with a molecular link to disease.
We describe the main underlying mechanisms that give rise to such N-terminal
proteoforms, these being splicing, initiation of protein translation, and protein
modifications. Given their role in several human diseases, it is becoming
increasingly clear that several of these N-terminal proteoforms may have po-
tential as therapeutic interventions and/or for diagnosing and prognosing
their associated disease.teoforms, with several of these pro-
teoforms contributing directly to human
diseases.
In the future, specific N-terminal
proteoforms might be targets for thera-
peutic intervention and/or usedasproxies
for disease diagnosis and prognosis.
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In GENCODE, the number of human protein-coding genes is at 20 454 [1]. However, the full
collection of chemically different human proteins is impossible to predict. This much higher
number of so-called proteoforms (see Glossary) compared with protein-coding genes stems
from gene transcription (the use of different promoters), processing of immature mRNA molecules
(alternative splicing), translation (alternative translation initiation, ribosomal frameshifting, and
stop codon read-through), and a vast number of protein modifications [2–4] (Figure 1A–C).
One specific type of proteoform are those that stem from the same gene, but differ at their
N termini, which we call ‘N-terminal’ proteoforms. Such proteoforms may hold extended,
truncated, and/or modified N termini with respect to the canonical protein (the term ‘canonical’
is used here as defined in the UniProtKB/Swiss-Prot database) and the mechanisms leading to
their production are diverse. In eukaryotes, the canonical mechanism for translation to start involves
a ribosome assembling at the 5′ end of a mature mRNA molecule, which then starts scanning for
start codons towards the 3′ end. Alternative start codons can be used for translation by various
mechanisms. For instance, secondary RNA structures may hinder ribosome scanning and thereby
promote translation to initiate from other codons [5]. Translation can also start at internal ribosomal
entry sites (IRES, Box 1) [6] and upon leaky scanning, in which the first encountered start codon is
embedded in a suboptimalKozak consensus sequence and ribosomes scan for a downstream
start codon present in a more optimal context [7] (Figure 1D). Other mechanisms include
translation re-initiation after a short upstream open reading frame (ORF) [8,9] (Figure 1E),
and 5′ mRNA leader sequence recapping [10]. In addition, alternative splicing may give
rise to transcripts that have different 5′ ends and these, possibly combined with alternative
translation initiation, may also give rise to N-terminal proteoforms [11,12] (Figure 1).
By using ribosome profiling data to yield an adapted search space for mass spectrometry data, it
was shown that 10–20% of all identified protein N termini in several human and mouse cells
originated from alternative translation initiation or alternative splicing (Box 2). Furthermore, several
of these N-terminal proteoforms were found to be conserved, hinting at a potential biological
importance [3,13]. Besides these mechanisms, protein processing may also lead to functional
N-terminal proteoforms. Protein processing is involved in protein maturation (e.g., initiator
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Glossary
5′ mRNA leader sequence
recapping: the 5′ end of mRNA
molecules can be truncated by
endoribonucleases or following the partial
degradation by 5′ exoribonucleases by
either secondary mRNA structures or
RNA-binding proteins. This leads to
shorter mRNA molecules, which can be
recapped by recapping enzymes. As a
consequence, these mRNA molecules
can be translated but might differ in their
5′ region, which leads to N-terminal
proteoforms.
Alternative translation initiation:
initiation of translation on mRNA
molecules at start codons that differ from
the canonical start codon, or by
translation initiation at an internal
ribosome entry site. Both lead to the
production of N-terminal proteoforms.
Kozak consensus sequence: a
nucleotide sequence motif found in
eukaryotic mRNA that surrounds the start
codon and promotes translation initiation.
The sequence is noted as gccRccAUGG,
in which the capital letters are highly
conserved and R can either be an
adenine or guanidine. Lower-case letters
represent the most occurring base at that
position, but these vary more and, thus,
are less conserved.
N-terminal proteoforms: proteoforms
that chemically differ at their N termini.
Proteoform: the proteoform definition
was introduced to describe all chemically
different forms in which the protein
products of a single protein-coding gene
appear. As such, differences in the actual
protein sequence due to genetic variation,
alternative promoter usage, alternative
splicing, alternative translation initiation,
and proteinmodifications are captured by
this definition.
Translation re-initiation: the small
ribosomal subunit remains attached to
the mRNA following termination of
translation. It resumes scanning on the
same RNA molecule and can initiate
again at a downstream start codon.
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thus, new N-terminal proteoforms), for example, N-terminomics studies, have identified novel
N-terminal proteoforms. A striking example is a study by Lange and coworkers, which identi-
fied a large number of processed protein products that appeared to be stabilized by post-
translational N-terminal acetylation in human erythrocytes [14]. Given that this review focuses
on (post)transcriptional and co-translational events leading to N-terminal proteoforms, we do
not discuss post-translational events giving rise to functional N-terminal proteoforms further.
Until recently, (N-terminal) proteoforms had often been overlooked, but studies on their biological
function are now emerging and show that the N terminus of a proteoform may influence the
stability, subcellular localization, and functionalities of a protein, and its interactions with other
proteins [15–20]. Although a recent review stressed the importance of studying proteoforms in
health and disease [21], N-terminal proteoforms arising from alternative start sites were not
discussed. Here, we fill this gap and review recent findings on the involvement of N-terminal
proteoforms (although not solely arising from alternative translation initiation) in human disease
(Table 1, Key Table).
Alternative Splicing Adds a Layer of N-Terminal Complexity
Nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) has twomajor isoforms called NFATc1-α
and NFATc1-β, the expression of which is regulated by different promoters. NFATc1-α is NFAT in-
ducible and results from splicing out the second exon, while NFATc1-β is expressed at basal levels
and transcribed from the second exon, which results in two N-terminal proteoforms [22,23].
Upon T cell receptor engagement and NFAT protein activation, NFATc1-α is massively expressed,
exceeding the expression levels of NFATc1-β several times [24]. The N termini of these
proteoforms have a transactivation domain (TAD) that has several functions [24]. In NIH 3T2
cells, NFATc1-α was found to increase cell proliferation and to induce several hallmarks of cell
transformation. By contrast, NFATc1-β reduced cell proliferation and increased cell death (by
increasing FasL and TNF-α levels) due to an acidic activation domain (AAD) only present in the
TAD of NFATc1-β. When these NFATc1 proteoforms were expressed in mice, NFATc1-α induced
large tumors with a high growth rate, whereas the β-proteoform induced smaller tumors with mod-
erate growth rates. Additionally, human peripheral blood mononuclear cells obtained from patients
with Burkitt lymphoma showed high levels of NFATc1-α and low levels of NFATc1-β, while the
same cells from healthy donors showed lower levels of NFATc1-α compared with NFATc1-β.
These data suggest that a specific NFATc1 proteoform is involved in tumor formation. Given that
NFATc1-α andNFATc1-βmay be involved in different cellular functions, deregulation of proteoform
expression could contribute to tumorigenesis. In addition, in Burkitt lymphoma, sustained activity of
NFATc1 has been linked to diffuse large B cell lymphoma, T cell acute lymphoblastic leukemia,
chronic lymphocytic leukemia, melanoma, and pancreatic and colorectal carcinomas [24].
The cytoplasmic tyrosine-protein kinase BMX, or epithelial and endothelial tyrosine kinase (ETK),
is a nonreceptor tyrosine kinase with functions in several cellular processes [25]. ETK/BMX regu-
lates the activity of proteins such as PI3-AKT, TNFR2, PAK1, TP53, PIM, and STAT3, and has an
important role in inflammation. It is overexpressed in several tumor types and its inhibition reduces
tumor cell proliferation and angiogenesis [26,27]. Ibrutinib, an FDA-approved drug to treat mantle
cell lymphoma and chronic leukemia by inhibiting Bruton’s tyrosine kinase (BTK), a member of the
BMX/ETK family, also inactivates BMX-STAT3 in glioma stem cells and impairs tumor growth [28].
Recently, an N-terminal proteoform of BMX/ETK, resulting from skipping exons 1–8, was found
in 21 out of 174 lung adenocarcinoma samples, while it was absent in control samples [29].
This N-terminal proteoform was dominant in tumor samples that had low to no expression of
the canonical ETK/BMX proteoform and was associated with the epidermal growth factor2 Trends in Biochemical Sciences, Month 2020, Vol. xx, No. xx
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tumor cell migration and facilitate cell transformation [29].
The ribosomal protein S6 kinase proteins (S6K1 and S6K2) are serine/threonine kinases that be-
long to the AGC kinase family and are downstream effectors of themammalian target of rapamycin
(mTOR). mTOR/SK6 targets multiple proteins that control protein translation and regulate path-
ways such as cell growth and/or size, proliferation, cell cycle progression, and metabolism.
mTOR/SK6 has important roles in physiology and diseases, including diabetes, cancer, aging,
organ growth, learning, and obesity (reviewed in [30]). S6K1 and S6K2 share 84% identity in
their kinase domains and 43% and 59% identity in their N- and C-terminal domains, respectively.
The most extensively studied S6K1 has two N-terminal proteoforms, p70S6K1 (or S6Kα2), which
contains 502 amino acids and is localized in the cytosol, and p85S6K1 (or S6Kα1), the longest
proteoform, containing an additional 23 N-terminal amino acids including a nuclear localization se-
quence. p85S6K1 can be secreted and enter surrounding cells via its N-terminal 6-arginine
repetition motif, which resembles a motif in the HIV TAT protein with similar properties [31].
Secreted p85S6K1 increases phosphorylation of its targets, cell size, and cell migration, which are
innate phenotypes of cancerous cells. In vivo, this proteoform promoted tumor growth of breast
cancer cells and lung metastasis, suggesting it as a target to treat breast cancer [31].
N-Terminal Proteoforms Generated by Alternative Translation Initiation
Caveolin-2 (cav-2α) is involved in insulin signaling and localizes in the plasma membrane, where it
recruits the insulin receptor and regulates the initiation of insulin receptor substrate-1 directed
signaling. Cav-2β is translated from a downstream AUG start codon (methionine-14) and
predominantly expressed in insulin-resistant obese subjects, where it desensitizes the insulin
receptor via dephosphorylation, leading to its lysosomal degradation and causing insulin resis-
tance [32] (Figure 2).
Endoplasmic reticulum membrane sensor NFE2L1 (NRF1) is a transcription factor essential for
maintaining cellular homeostasis, organ development and growth, and the adaptive response
to pathophysiological processes. NRF1 dysfunction is associated with diabetes, liver cancer,
and other malignancies [33,34]. Canonical NRF1 (Nrf1α) is yielded by alternative splicing, skipping
exon 4 from the main ORF. A shorter form, Nrfβ, is in-frame translated from an internal Kozak
sequence located around the four methionine codons between positions 289 and 297 in the
sequence of the mouse protein. A third, smaller proteoform, Nrf1γ, is produced by either in-
frame translation starting at methionine 584 and/or by proteolytic processing of the longer Nrf1
proteoforms. These Nrf1 proteoforms regulate different sets of homeostatic and developmental
target genes, which are involved in several pathological processes [33,34]. Nrf1α and Nrf1β
account for the main Nrf1-mediated transcription of downstream genes. Nrf1γ acts in a
dominant-negative manner, leading to the downregulation of several key genes, some of which
are targets of Nrf1α and Nrf1β. Nrf1γ most likely interferes with the functional assembly of active
transcription factors (Nrf1α, Nrf1β, and Nrf2) [34].
Thrombocytopenia 2 is caused by monoallelic mutations in the 5′-untranslated region (UTR) of
ANKRD26. Patients with this disease also have an increased risk of developing acute myeloid
leukemia (AML). To find the molecular link between both diseases, Marconi et al. screened theFigure 1. Examples of how N-Terminal Proteoforms Are Generated. A single protein-coding gene may give rise to different N-terminal proteoforms by (A) alternative
promoter usage, (B) alternative splicing leading to transcripts differing at the 5′ end, and (C) alternative translation initiation. The two major mechanisms leading to alternative
translation initiation are (D) leaky scanning, where the first start codon located in aweakKozak sequence (indicated in light pink) is skipped, and translation starts from a second
start codon located in a more optimal Kozak sequence, (indicated by dark pink), and (E) translation re-initiation, in which the small ribosomal subunit remains attached to the
mRNA after it passes a stop codon and can re-initiate translation at a downstream start codon. Abbreviations: ORF, open reading frame; UTR, untranslated region.
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Box 1. Cellular Stress and Cap-Independent Translation
Cap-dependent initiation of translation, being the assembly of the ribosome at the 5′ end of a mRNA molecule to start
scanning towards the 3′ direction for start codons, was long seen as the only possibility to initiate translation of eukaryotic
mRNA molecules. However, the discovery of an alternative mode of translation initiation of viral transcripts in eukaryotic
cells changed this view [67]. In this cap-independent scanning mode, the 40S ribosomal subunit is directly recruited to
an internal ribosome entry site (IRES) to start translation and this gives rise to N-terminal proteoforms [5]. IRES translation
is favored when cap-dependent translation is blocked, as, for instance, in various pathophysiological stress conditions
(e.g., amino acid starvation, apoptosis, and hypoxia) and during cell cycle progression, cell differentiation, and cell devel-
opment [68,69]. IRES translation is known to contribute to several pathological states, such as Alzheimer’s disease [70],
several tumors, and cancers, such as glioblastoma and breast cancer [71]. Given that most papers on IRES-dependent
translation are less than recent, besides indicating here a link between IRES and disease, we do not consider this particular
aspect of N-terminal proteoform formation further here.
Box 2. Detecting a N-Terminal Proteoform Can Be Challenging
Mass spectrometry-driven proteomics has been a key method to identify N-terminal proteoforms. Of note, whereas
ribosomal footprinting led to lists of thousands of rather unexpected, even near-cognate, translation initiation sites,
disappointingly, only a minor fraction of these has been detected by means of proteomics. One important aspect to
consider is that there is generally just one peptide per N-terminal proteoform that verifies its presence in a sample,
that is, its furthest N-terminal peptide. Without any enrichment of such peptides, the presence of higher numbers of
non-N-terminal peptides (e.g., in a bottom-up, shotgun proteomics experiment) will hinder the identification of the N-terminal
peptides. In addition, especially for cytosolic eukaryotic proteins, protein N termini are frequently acetylated in vivo, which
makes the corresponding N-terminal peptides less basic, and this may interfere with their ionization, thus lowering the overall
sensitivity of their detection. This acetyl group could also interfere with the actual fragmentation of peptide ions in the fragmen-
tation cell of the mass spectrometer, thereby yielding ill-predicted peptide fragmentation patterns that may interfere with the
actual matching of a theoretical peptide sequence to an experimental fragmentation spectrum.
Another important aspect to consider is the actual search space that is used to identify the peptides. For instance, in-frame
translation starting at downstream or upstream near-cognate start codons yields proteoforms of which the exact identity
of their N-terminal parts is not necessarily captured in protein sequence databases. Indeed, such translation starting at
downstream start codons is expected to yield a proteoform starting with an initiator methionine, whereas another amino
acid might be indicated in the stored protein sequence. One way to overcome this is to merge ribosomal footprinting
data to protein sequence data, although this increases the size of the database at the expense of losing overall coverage
of N-terminal proteoforms.
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Trends in Bioch5′UTR and exon 1 of ANKRD26 in 250 patients with AML. Three patients carried two different
variants in the 5′ end of the ANKRD26 coding region, c.3GNA or c.105CNG, resulting in the pro-
duction of two different N-terminally truncated proteoforms of ANKRD26. These proteoforms
maintain ANKDR26 functionality and lead to even stronger activation of the MAPK/ERK pathway.
ERK hyperactivation leads to thrombocytopenia and could contribute to the predisposition to
myeloid malignancies [35].
Chromosomal aneuploidy and specific gene mutations are early hallmarks of many oncogenic
processes. The most common form of aneuploidy is trisomy of chromosome 21, causing
Down’s syndrome. Patients with Down’s syndrome often show hematopoietic abnormalities,
such as transient myeloproliferative disorder (TMD), which can progress to AML. These patients
with TMD carry GATA1 mutations that lead to the production of a GATA1 short variant (GATA1s)
by translation from methionine-84. Trisomy 21 perturbs normal hematopoietic development
through the enhanced production of early hematopoietic progenitors and increases the expres-
sion of GATA1s, causing excessive aberrant differentiation of megakaryocytes. Several genes
(RUNX1, ETS2, and ERG) located at a critical 4-Mb region of chromosome 21, of which expres-
sion levels are increased, mediate this effect [36].
Cellular tumor antigen p53 (p53) is one of the best-known proteins associated with cancer.
Known for its tumor-suppressor activities, mutant and dysfunctional p53 proteins, as well asemical Sciences, Month 2020, Vol. xx, No. xx 5
Key Table
Table 1. Overview of Recently Discovered N-Terminal Proteoforms with a Link to Disease
Gene Proteoforms Link to human disease Refs
Alternative splicing
NFATC1 NFATc1-α and NFATc1-β produced by combination of different
promoters for transcription and alternative splicing
NFATc1-α is involved in tumor formation, while NFATc1-β acts
as an anti-oncogenic factor; involved in several cancers, such
as leukemia, lymphoma, and pancreatic and colorectal
cancers
[24]
BMX ΔEx1-8 BMX results from skipping exons 1–8 ΔEx1-8 BMX was dominantly expressed in 21 out of 174 lung





S6K2 p85S6K1 contains 23 more N-terminal amino acids than
the p70S6K1 proteoform, including a 6-arginine repetition
motif




CAV2 Second AUG-codon (Met-14) of Cav-2 is used as internal
translational start site. Resulting shorter 18 kDa Cav-2β
proteoform lacks 13 amino acids at its N terminus
Caveolin-2β causes insulin resistance [32]
NRF1 Nrf1α (full length); Nrf1β lacks the first 296 amino acids; and
Nrf1γ starts at position 584 resulting from alternative translation
initiation; Nrf1γ might also be produced by endoproteolytic
processing
These proteoforms transcribe distinct subsets of target genes
that are involved in cancer, neurodegeneration, and diabetes.
Nrf1γ is dominant negative over the other two proteoforms
[34]
ANKRD26 Mutants c.3GNA and c.105CNG lead to N-terminally truncated
variants of ANKRD26
Mutations found in patients with acute myeloid leukemia (AML);
cause overexpression of ANKDR26 and hyperactivation of
MAPK/ERK signaling pathway, both of which are linked to
thrombocytopenia and AML
[35]
GATA1 Mutations lead to GATA1-S, a shorter form starting at
methionine-84
Related to Down’s syndrome, in which mutations lead to sole
production of GATA1-S, in turn leading to RUNX1/ETS2/ERG-
mediated hyperproliferation of aberrant megakaryoblasts
resulting in transient myeloproliferative disorders
[36]
TP53 Δ40p53 is a N-terminal truncated proteoform resulting from
alternative splicing and/or alternative translation initiation at AUG-40
Predominant element of amyloid aggregates and proposed key
modulator of p53 tumor suppression and oncogenic activities in
endometrial carcinoma
[38]
Δ40p53 suppresses tumor proliferation, induces cellular
senescence, and upregulates p53 expression in hepatocellular
carcinoma cells
[39]
PTEN PTEN-L arising from translation starting at an upstream CUG codon PTEN and PTEN-L are depleted in renal carcinoma cells;
expression of PTEN-L acts as a tumor suppressor and this
protein is considered to be a potential therapeutic target
because it can enter cells
[42]
SOX-9 Mutation creates upstream translation initiation start codon Leads to acampomelic campomelic dysplasia [43]
GRHPR Two variants in the 5′UTR on separate alleles: c.-4GNA andc.-3CNT
occurring in cis creating out-of-frame alternative start site
Alternative translation initiation creates 20-amino acid peptide
with no relation to GRHPR and causes reduced levels of
GRHPR, which results in primary hyperoxaluria type II
[44]
RUNX1 Translation occurs at Met-1 and Met-25, giving rise to full-length
RUNX1 and a shorter protein, lacking the first 24 amino acids
(RUNX1ΔN24)
Retains hematopoietic activity. Translation initiation from Met-25
may act as a fail-safe mechanism to maintain normal
hematopoiesis when production of full-length RUNX1 protein is
inhibited by genetic mutations
[45]
N-terminal modifications
APP Several N-terminal proteoforms Proteoforms are enriched in Aβ soluble aggregates, a hallmark
of Alzheimer’s disease
[46]
CST3 Three N-terminal truncations: desS-, des-SSP, and des-SSPG des-S and des-SSP proteoforms are enriched in patients with
type 2 diabetes mellitus and chronic kidney disease, while
des-SSPG has been found in intracystic fluid of pilocytic
astrocytoma pediatric brain tumors
[49,50]
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Table 1. (continued)
Gene Proteoforms Link to human disease Refs
PPARGC1A N-terminal acetylation by NAA10 Pgc1α N-terminal acetylation by NAA10 prevents its binding to
PPARγ and the subsequent expression of thermogenic genes.
Absence of this N-terminal acetyl group prevents diet-induced
obesity
[53]
H4 Loss of N-terminal acetylation by Nat4 Absence of N-terminal acetyl group induces specific
stress-response genes
[55]
MeCp2e1 Missense mutation in exon 1 (c.5CNT) that results in a Ala2Val Leads to Rett syndrome [57]
SNCA N-terminal acetylation Reduces aggregation of α-Syn that mostly comprises Lewy
bodies, a hallmark of Parkinson’s disease
[62–65]
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localization of p53 proteoforms (canonical p53, Δ40p53, and Δ133p53) were analyzed in
endometrial carcinoma (EC) cells and endometrial nontumor cells [38]. Canonical p53 was
found to contain the conserved N-terminal TAD. Δ40p53 proteoforms are truncated proteins
resulting from alternative splicing of exon 2 and/or from translation initiation at in-frame AUG-40
[38,39] and lack part of the conserved N-terminal TAD. The Δ133p53 proteoforms result from
translation initiation at AUG-133, and lack the entire TAD and part of the DNA-binding domain.
Δ40p53 and canonical p53 are the main p53 forms in EC tumor cells, while Δ40p53 is
the main form in nontumor cells. Δ40p53 mainly localizes to cytoplasmic punctate structures of
EC cells, where it is the major component of amyloid aggregates. The N-terminal TAD domain
significantly reduces aggregation of the p53 DNA-binding domain, which confirms the higher
aggregation tendency of Δ40p53, which partially lacks this domain [38]. Previous studies pointed
out that p53 mutants exert a dominant-negative regulatory effect over canonical p53 by
converting the latter into aggregated species that acquire a gain-of-function phenotype by loss
of their tumor suppressor roles [40].
Another study onΔ40p53 assessed its effect in hepatocellular carcinoma cells (HCC). Expression
of Δ40p53 in these cells reduced colony formation and cell survival by inducing cellular
senescence (G1 cell cycle arrest). Δ40p53 also increased the expression of several genes
(includingMDM2, FAS, and p21), indicating that it exerts its tumor-suppressor activity by promot-
ing p53-induced gene expression. Furthermore, Δ40p53 also upregulated expression of canon-
ical p53. These results demonstrate that Δ40p53 exerts tumor-suppressor activity by inducing
cellular senescence, at least partly by upregulating p53 target gene expression in HCC [39]. Of
note, these studies on Δ40p53 nicely demonstrate that a given proteoform can have opposing
roles in different cancers.
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phospha-
tase (PTEN) is another well-known tumor-associated protein. In 2013, Hopkins et al. [41] identi-
fied a N-terminally extended proteoform, PTEN-Long (PTEN-L), with a 173-amino acid extension
that holds a secretion signal, a 6-arginine repetition similar to that of the HIV TAT protein men-
tioned earlier. PTEN-L was found to be secreted and imported by other cells, and had the
same functionalities as canonical PTEN. In a mouse tumor model, PTEN-L uptake inhibited the
PI3K pathway and tumor growth. Based on this study, Wang et al. analyzed the role and thera-
peutic significance of PTEN-L in renal cell carcinogenesis (RCC) [42]. Akt was demonstrated
to control the balance between cell survival and apoptosis, and most likely has a role in carcino-
genesis and progression in RCC by its elevated activity. Furthermore, compared with normal
tissue, in RCC cells, PTEN and PTEN-L levels were reduced or even not detected (with the levels
of PTEN-L being more reduced than those of PTEN) and the levels of activated Akt wereTrends in Biochemical Sciences, Month 2020, Vol. xx, No. xx 7
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Figure 2. An N-Terminal Proteoform of Caveolin-2 (Cav-2α), Caveolin-2β, Causes Insulin Resistance. Cav-2α is involved in insulin signaling and is localized in
the plasma membrane, where it recruits the insulin receptor and regulates the initiation of insulin receptor substrate-1-directed signaling. Cav-2β, the main Cav-2 form in
insulin-resistant cells, is a shorter proteoform that desensitizes the insulin receptor via dephosphorylation by protein tyrosine phosphatase 1B (PTP1B), leading to its
lysosomal degradation and causing insulin resistance. Abbreviation: ER, endoplasmic reticulum.
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levels by 90%, inhibited cell proliferation, migration, and invasion, and induced apoptosis.
Furthermore, mice carrying tumors that were injected with PTEN-L showed tumor regression8 Trends in Biochemical Sciences, Month 2020, Vol. xx, No. xx
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pacity of PTEN-L against RCC [42].
The transcription factor SOX-9 regulates the expression of genes involved in skeleton development
and sex determination. Approximately 70 mutations in SOX-9 have been linked to (a)campomelic
dysplasia or (A)CD, a disease characterized by several skeletal malformations and bending, respi-
ratory distress, and hearing loss, and causing a high mortality rate in neonates and infants. ACD
appears as a milder form of CD with less severe symptoms and better prognosis. Most mutations
causing CD prevent SOX-9 production or lead to the production of a protein product with impaired
functionality. In ACD, it is presumed that residual SOX-9 is produced. Evidence for this comes from
a single case study that reported on a patient with ACD with no mutations in the SOX-9 coding
sequence or intron/exon boundaries, but with a mutation in the 5′UTR sequence, a heterozygous
mutation, c.-185GNA. This mutation gives rise to a novel upstream AUG (uAUG) translation initia-
tion codon, also surrounded by a better Kozak sequence, 185 nucleotides before the normal
AUG start codon. This uAUG creates a novel upstream ORF (uORF) of 62 codons out-of-frame
with the normal ORF and terminates just after the wild-type start codon. Although this new starting
site was mainly used for translation, still some, albeit strongly reduced, expression of canonical
SOX-9 was observed, leading to the milder CD form [43].
Another example is glyoxylate reductase/hydroxypyruvate reductase (GRHPR). Mutations in this
gene lead to the recessive genetic disorder primary hyperoxaluria type II. A genetic screen on a pa-
tient revealed two variants in the 5′UTR of GRHPR on two separate alleles (c.-4GNA and c.-3CNT).
When these two occur in cis, a new out-of-frame translation initiation start site is created. This start
site is embedded in a more ideal Kozak sequence and highly translated, leading to a 20-amino acid
peptide with no relation to GRHPR. As a consequence, GRHPR translation is strongly reduced [44].
Runt-related transcription factor 1 (RUNX1) is essential for hematopoiesis and its disruption leads to
hematopoietic diseases. For instance, in leukemia, RUNX1 has a growth-promoting role. AN-terminal
RUNX1 proteoform starting at methionine-25 is produced by alternative translation initiation. This
proteoform has an enhanced stability, retains functionality, and its expression is competitive with
that of canonical RUNX1. Therefore, this proteoform might act as a fail-safe mechanism to maintain
normal hematopoiesis when, due to mutations, production of full-length RUNX1 is inhibited [45].
On the Influence of N-Terminal Modifications
Soluble and insoluble aggregates of amyloid-beta (Aβ) protein have a role in the pathogenesis
of Alzheimer’s disease (AD). Analysis of aggregates from human AD brains by nano-liquid chroma-
tography tandem mass spectrometry pointed to a heterogeneous population of Aβ proteoforms,
including proteoforms starting at seven different positions [46]. N-terminal truncations were found
to bemore abundant in the insoluble aggregates due to the removal of the hydrophilic region located
in the N-terminal part, while C-terminal proteoforms were enriched in the soluble aggregate fraction.
Although soluble aggregates are themost toxic forms of Aβ [47], additional investigation is needed to
determine the biological function and clinical relevance of all these proteoforms in AD.
Cystatin C (CysC) is a cysteine proteinase inhibitor used as a proxy for kidney function. In a study
of 500 human plasma samples from a control population, two CysC proteoforms were reported
as consequence of N-terminal truncations, onemissing the N-terminal serine (des-S) and another
lacking three N-terminal residues (des-SSP) [48,49]. Quantitative mass spectrometry immunoas-
says of CysC proteoforms in a cohort of patients with chronic kidney disease (CKD) with or with-
out type 2 diabetes mellitus, showed that the levels of des-S and des-SSP were greater in the
diabetic CKD group and could be used as markers for CDK progression [50]. A third CysCTrends in Biochemical Sciences, Month 2020, Vol. xx, No. xx 9
Outstanding Questions
To what extent is the collection of
N-terminal proteoforms found in human
cell lines or even primary cells identical
to that found in human tissues?
Are there different N-terminal pro-
teoforms, originating from the same
gene, in different tissues?
Which N-terminal proteoforms have
critical roles in biological or pathologi-
cal processes, and which are simply
the result of differences in transcrip-
tion, splicing, translation, and modifi-
cations and are not causing any harm
to the cells or tissues?
Which (external) factors cause the
generation of N-terminal proteoforms?
Trends in Biochemical Sciences
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proteomic study of intracystic fluid from a pilocytic astrocytoma pediatric brain tumor [49].
Removal of the initiator methionine and N-terminal acetylation are highly conserved and
widespread modifications that mostly occur co-translationally. Mutations in the NAA10 gene,
which encodes N-alpha-acetyltransferase 10 (ARD1), which has the highest substrate repertoire,
lead to NAA10 syndrome. The first described NAA10 mutation was the Ser37Pro mutation [51],
which impairs the interaction of NAA10 with Naa15 and Naa50 and leads to decreased N-terminal
acetylation of several substrates [52]. This NAA10 mutation was linked to the lethal Ogden syn-
drome. NAA10 also has a role in high-fat diet (HFD)-induced obesity [53]. Naa10 knockout (KO)
mice fed a HFD showed reduced weight gain and reduced body fat compared with wild-type
mice. Further studies revealed that a Naa10 KO resulted in increased expression of thermogenic
genes and this was linked to the absence of N-terminal acetylation of Pgc1α. The N terminus of
Pgc1α is normally acetylated by NAA10, which prevents its interaction with PPARγ. Given that
this interaction normally leads to increased expression of thermogenic genes, the absence of the
N-terminal acetyl group explains why a NAA10 KO results in an increased expression of such
genes [53]. In addition, NAA10 overexpression is also found in several cancers, where it correlates
with low survival rate and the aggressiveness of tumors [54].
Post-translational modifications on histones are part of the epigenetic system that regulates
chromatin structure and condensation, and DNA replication, repair, and transcription. Loss of
N-terminal acetylation of histone H4, due to low levels of N-terminal acetyltransferase 4 (Nat4),
was directly related to longevity driven by calorie restriction. Calorie restriction reduces the levels
of Nat4, resulting in reduced levels of N-terminal acetylated H4, which induces specific stress-
response genes [55].
The methyl CpG-binding protein 2 (MeCp2) is a chromatin-associated transcription factor with
two described isoforms, MeCp2e1 (MeCp2B) and MeCp2e2 (MeCp2A), due to the switch
between translation start codons in exons 1 and 2, respectively. Among the mutations in the
MECP2 gene that lead to clinical manifestations of Rett Syndrome, there is a missense mutation
in exon 1 (c.5CNT) that results in a Ala2Val mutation [56]. This residue is conserved throughout
evolution and located in a region with multiple binding sites for the transcription factor SP1.
Sheikh et al. found that the mutated proteoform MeCp2e1-Ala2Val was less stable than the
wild-type protein due to reduced initiator methionine cleavage and reduced N-terminal acetylation
of either methionine or valine [57].
The N-terminal acetylation of α-synuclein (α-Syn or NACP) was extensively characterized in view
of the functional and pathological role of this protein [58]. Intracellular inclusions of aggregated
and misfolded α-Syn comprising the Lewy bodies are a hallmark of Parkinson’s and other neuro-
degenerative diseases [59]. N-terminal acetylation stabilizes the N-terminal domain helicity, which
confers increased affinity for membrane interaction [60,61], and decreases α-Syn aggregation by
blocking the formation of hydrogen bonds, which contribute to α-Syn oligomerization [62–65].
Concluding Remarks
N-terminal proteoforms arise from different transcription and translation-related mechanisms, in
addition to mutations leading to differences in transcript sequences. Besides increasing the over-
all chemical complexity of a proteome, some N-terminal proteoforms have been linked to dis-
eases, as we have discussed (see Outstanding Questions). The roles of such proteoforms in a
given disease may also be subject to other cellular factors. For instance, the N-terminal
proteoform of p53 arising from translation starting at methionine-40 causes aggregation of10 Trends in Biochemical Sciences, Month 2020, Vol. xx, No. xx
Box 3. Global and Functional Analysis of N- and C-Terminal Proteoforms
A recent study in mouse brain set out to map proteoforms in a global way. By combining ribosome footprinting and liquid
chromatography tandem mass spectrometry (LC-MS/MS), N-terminal proteoforms resulting from alternative translation
initiation andC-terminal proteoforms resulting from stop codon read-throughwere identified. Interestingly, these proteoforms
were found to be differentially expressed in different cell types (neuron and glia cells) and upon neuron depolarization [66].
Among the proteoforms detected, an Uchl1 proteoform lacking 15 N-terminal amino acids was identified. Uchl1 is
a deubiquitinating protease with protective roles in neurodegeneration and AD. For the C-terminal proteoform of AQP4,
differential regulation of the normal and extended proteins in pathological conditions (involving gliosis) was found [66].
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Trends in Biochefull-length p53, removing its tumor suppressor role in endometrial carcinoma cells [38],
whereas it exerts tumor suppressor activity in HCC [39].
The fact that N-terminal proteoforms appear to hold important functions in different diseases may
open avenues for new therapies. As an example, specific inhibition of NFATc1-α with a tumori-
genic signaling role, and not of NFATc1- β with tumor-suppressive abilities, appears to be an in-
teresting route for future anticancer drug design [24]. In addition, some N-terminal proteoforms
could be seen as potential biomarkers and, thus, one could envision applied methods, such as
targeted proteomics and antibodies, specifically recognizing N-terminal epitopes for diagnostic
purposes.
Of note, most N-terminal proteoforms were discovered in studies focused on single proteins. To
date, there is only one widescale study that maps N-terminal proteoforms in mouse brain and
their relation to functionality (Box 3 and [66]). Thus, this emerging field appears to be gaining
attention. Along this line, it is somewhat disappointing that the term ‘proteoform’ is not yet widely
used, rather one mentions isoforms. Therefore, it is not straightforward to mine public data for
functionalities of N-terminal proteoforms and, thus, we encourage researchers to consider
when to use the term ‘proteoform’ and when to use the term ‘isoform’. In fact, in studies reporting
on peptide and protein sequences, we do recommend the use of the term ‘proteoform’ as
defined by Smith and Kelleher [2] because it embraces all different chemical structures of the
protein products from a single gene. As such, it includes possibly different proteins that originate
from genetic variation, RNA transcript variation, and protein modification. This is different from the
term ‘isoform’ as used by popular protein sequence databases, such as UniProt. This term only
includes alternative protein sequences arising from alternative promoter usage, alternative
splicing, alternative translation initiation and/or ribosomal frameshifting and, hence, does not
consider protein modifications.Acknowledgments
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